Autologous TBX-4000-treated Peripheral Blood Mononuclear Cells TBX-3400

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** An autologous cell preparation in which the autologous peripheral blood mononuclear cells (PBMCs) are treated ex vivo with TBX-4000, a recombinant TAT-MYC fusion protein, with potential antineoplastic and immunomodulating activities. Upon reintroduction of the TBX-3400 cells into the patient, the generated T-cells may activate the immune system and exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. The TBX-4000 recombinant fusion protein consists of the N-terminal 9 amino acid segment of the HIV TAT protein transduction domain (PTD) fused to the MYC protein. TBX-4000 TAT-MYC rapidly localizes to the nucleus and transiently provides signals to drive proliferation and survival of T-cells.

**Synonyms:** - Autologous PBMCs TBX-3400 - Autologous TBX-4000-treated Human PBMCs - TBX 3400 - TBX-3400 - TBX-3400 Cells